NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal...( EMERYVILLE Calif. March 7 /- NovaBay ...),Health

EMERYVILLE, Calif., March 7 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Alternext: NBY), a mid-stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective products for the treatment and prevention of a wide range of bacterial, fungal, and viral infections without developing resistance, today announced preclinical animal data showing that NVC-422, the Company's lead Aganocide(R) compound, was effective in treating subcutaneous dermatophyte (skin fungus) infections.

The study of NVC-422, which is a synthetic bioequivalent form of the most effective and rapidly-acting anti-infective molecules produced by white blood cells, revealed significant clinical and mycological efficacy compared to the untreated control group at all doses evaluated, with the highest clinical and mycological efficacy rates of 36.6% (p <0.0001) and 97.9% (p <0.05), respectively, achieved in the highest dose group. These data confirm previous preclinical results that showed a high level of activity for high dose NVC-422 against dermatophytes. The results were presented at the American Academy of Dermatology (AAD) 67th Annual Meeting in San Francisco (Abstract #2405).

"Dermatophytosis is a group of chronic and common skin infections that causes significant discomfort and cosmetic problems, and currently available drugs often do not provide adequate cure and cause unwanted side effects," said Mahmoud A. Ghannoum, Ph.D., Director of the Center for Medical Mycology, Department of Dermatology, University Hospitals of Cleveland, and Case Western Reserve University. "The significant clinical and mycological efficacy rates shown in this study demonstrate that topical NVC-422 penetrates the skin and hair at the infection site indicating that it has the potential to target and eliminate skin infections, including onychomycosis, tinea pedis, and tinea capitis. Importantly, these data provide strong s
'/>"/>